Argenica Therapeutics Ltd has released a press release.
ARG007 Shows Significant Neuroprotection in Concussion Study
Earlier from Argenica Therapeutics
- ARG007 (Xaranetide) Completes All Three FDA Requested Assays
- WHO Confirms Xaranetide as INN for ARG-007
- IND Application Advanced With Successful Completion of Assay
- Clinical Advisory Committee Established to Advance Phase 2b